-
FDA Approves Enhertu for HER2-Low and HER2-UltraLow Breast Cancer
•
The US Food and Drug Administration (FDA) has approved Enhertu (trastuzumab deruxtecan), an HER2-targeted antibody drug conjugate (ADC) co-developed by AstraZeneca (AZ, NASDAQ: AZN) and Daiichi Sankyo (TYO: 4568), for the treatment of adult patients with unresectable or metastatic hormone receptor (HR)-positive, HER2-low (IHC 1+ or IHC 2+/ISH-) or HER2-ultralow…
-
Immunophage Partners with GoBroad Cancer Hospital for IPG1094 Phase II Study
•
Nanjing-headquartered Immunophage Biotech Co., Ltd., a targeted therapy developer with operations in China, Australia, and the US, has announced a comprehensive partnership with Shanghai GoBroad Cancer Hospital and China Pharmaceutical University. The collaboration, which follows their initial alliance in December of last year regarding IPG7236, is focused on the Phase…
-
Betta Pharmaceuticals Gains NMPA Approval for BPI-452080 Clinical Study
•
China-based Betta Pharmaceuticals Co., Ltd (SHE: 300558) announced that it has received approval from the National Medical Products Administration (NMPA) to conduct a clinical study assessing its BPI-452080 in von Hippel-Lindau (VHL) syndrome-related tumors and solid tumors. This marks a significant step forward in the development of new treatments for…
-
Haisco’s HSK39004 Gains NMPA Approval for COPD Clinical Trials
•
China-based Haisco Pharmaceutical Group Co., Ltd (SHE: 002653) announced that it has received clinical trial approval from the National Medical Products Administration (NMPA) for its HSK39004. The targeted small molecule inhibitor is now cleared to be assessed in clinical trials for chronic obstructive pulmonary disease (COPD), marking a significant step…
-
Sino Medical Sciences’ NC Rockstar Catheter Gains MDA Approval in Malaysia
•
China-based Sino Medical Sciences Technology Inc. (SHA: 688108) announced that it has received marketing approval from the Medical Device Authority (MDA) of Malaysia for its NC Rockstar non-compliant coronary artery balloon dilation catheter. The device is designed for balloon catheter dilation of autologous coronary artery or bypass stenosis to improve…
-
Henan Lingrui to Acquire Yingu Pharma for RMB 704 Million
•
China’s Henan Lingrui Pharmaceutical Co., Ltd. (SHA: 600285) announced plans to acquire a 90% ownership stake in Yingu Pharmaceutical Co., Ltd. for a consideration of RMB 704 million (USD 97 million). The deal underscores Lingrui’s strategic expansion in the pharmaceutical sector, targeting Yingu’s innovative product portfolio. Yingu Pharma’s Innovative Nasal…
-
Junshi Biosciences Receives NMPA Approval for JS213 Clinical Trials
•
China-based Shanghai Junshi Biosciences Co., Ltd (HKG: 1877, SHA: 688180) announced that it has received clinical approval from the National Medical Products Administration (NMPA) for its JS213 sterile powder for injection. The drug is intended for use in combination with other anti-tumor drugs or as a standalone treatment for advanced…
-
ClouDr Group Integrates DeepSeeker R1 into CloudrBrain to Boost Chronic Disease Management
•
China-based ClouDr Group Limited (HKG: 9955) announced the integration of the DeepSeeker R1 model into its exclusive medical artificial intelligence (AI) product, CloudrBrain. The move aims to enhance CloudrBrain’s digital mining capabilities and improve the efficiency of chronic disease management through its hospital SaaS and pharmacy SaaS solutions. Enhancing AI-Driven…
-
Henlius’ Serplulimab Receives EU Approval for Extensive-Stage Small Cell Lung Cancer
•
China-based Shanghai Henlius Biotech Inc. (HKG: 2696) announced that it has received marketing approval from the European Commission (EC) for its serplulimab, combined with carboplatin and etoposide, as a first-line treatment for adult patients with extensive-stage small cell lung cancer (ES-SCLC) under the trade name Hetronifly. This approval marks serplulimab…
-
Harbour BioMed Receives NMPA Clearance for COPD Treatment HBM9378/SKB378
•
China-based biopharmaceutical company Harbour BioMed (HKG: 2142) has announced receiving clinical clearance from China’s National Medical Products Administration (NMPA) for its investigational drug HBM9378/SKB378, also known as WIN378. This fully human antibody targets thymic stromal lymphopoietin (TSLP) and is intended for the treatment of chronic obstructive pulmonary disease (COPD). Drug…
-
Tofflon to Join Shanghai Biomedical M&A Fund with Leading Firms
•
China-based Tofflon Science and Technology Group Co., Ltd. (SHE: 300171), a total solution service provider for global pharmaceutical companies, plans to jointly establish the Shanghai Biomedical Mergers and Acquisitions Equity Investment Partnership Enterprise (Limited Partnership) with Shanghai Pharmaceuticals Holding Co., Ltd., Shanghai Junshi Biosciences Co., Ltd., and MediTrust Health, among…
-
Becton Dickinson Considers Spinning Off Life Sciences Division
•
US-based Becton, Dickinson and Co. (BD) is reportedly considering spinning off its life sciences division, which is estimated to be valued at approximately $30 billion, according to sources cited by Reuters. The move is seen as a strategic effort to potentially boost the company’s stock price. Exploring Feasibility and TimingBD…
-
Vantive Launches as Standalone Vital Organ Therapy Company Post Carlyle Acquisition
•
Vantive, formerly the Baxter Kidney Care segment, has announced its launch as a new standalone vital organ therapy company following the completion of its acquisition by funds managed by global investment firm Carlyle (NASDAQ: CG) from Baxter International Inc. (NYSE: BAX). This marks a significant step in Vantive’s evolution as…
-
Nona Biosciences Partners with Invetx for Animal Health Therapies
•
Nona Biosciences (HKG: 2142), a wholly-owned subsidiary of HBM Holdings Ltd, has announced a partnership with US-based animal health company Invetx, Inc. Under the agreement, Invetx will utilize Nona’s HCAb Harbour Mice platform to develop next-generation biological therapies for animal health. Financial details of the partnership were not disclosed. Significance…
-
AbbVie Reports Strong Q4 and Full-Year 2024 Financials
•
US-based pharmaceutical giant AbbVie (NYSE: ABBV) has released its Q4 and full-year 2024 financial results, recording global net revenues of $15.102 billion (+5.6%) and $56.334 billion (+3.7%) respectively. Within these figures, the US market contributed $11.734 billion (+5.6%) and $43.029 billion (+2.7%) in net revenues during the fourth quarter and…
-
IASO Bio’s CAR-T Therapy Fucaso Accepted for Review in Singapore
•
China-based IASO Biotherapeutics has announced that a New Drug Application (NDA) for its BCMA-targeted chimeric antigen receptor (CAR) T cell therapy Fucaso (equecabtagene autoleucel) has been accepted for review by the Health Sciences Authority (HSA) of Singapore. The therapy is intended for the treatment of relapsed/refractory multiple myeloma (R/R MM)…
-
Novartis Reports 12% YOY Growth in Full-Year Net Sales
•
Swiss pharmaceutical major Novartis (NYSE: NVS) has released its Q4 and full-year 2024 financial report, showing a 12% year-on-year (YOY) expansion in constant currency terms. The company achieved net sales of $50.317 billion, with core operating profit up 22% to $19.494 billion. During the fourth quarter, net sales increased by…
-
Takeda Reports 4.5% Revenue Growth in First Nine Months of Fiscal Year
•
Japan-headquartered Takeda (NYSE: TAK, TYO: 4502) has released its financial results for the 9-month period ended December 31, 2024. The company reported revenues of JPY 3.53 trillion ($22.4 billion), representing a 4.5% growth at constant exchange rates (CER). Sales jumped 14.6% year-on-year (YOY) due to the growth period and continuous…
-
Daiichi Sankyo Reports 16.6% Revenue Growth in First Three Quarters of FY2024
•
Japan-based Daiichi Sankyo (TYO: 4568) has reported revenues of JPY 1.37 trillion ($8.927 billion) for the first three quarters of the fiscal year 2024 (April 1, 2024, to March 31, 2025), representing a 16.6% year-on-year (YOY) growth. Core operating revenue stood at JPY 248.311 billion ($1.621 billion), up 27.6% YOY.…
-
Pfizer Reports 7% Revenue Growth in 2024, Expects Steady Performance in 2025
•
US major Pfizer Inc. (NYSE: PFE) has released its financial results for the fourth quarter and full year of 2024. The company recorded revenues of $63.627 billion for the full year, up 7% year-on-year (YOY) in constant currency terms. Excluding COVID-19 products Paxlovid and Comirnaty, revenues grew by 12%. During…
